**Curriculum Vitae**

Wengen Chen, MD, PhD, MPH, FACNM

Associate Professor

Department of Diagnostic Radiology and Nuclear Medicine

University of Maryland School of Medicine

Director, Nuclear Medicine Residency Program

University of Maryland Medical Center, Baltimore, MD

**Date** July 1, 2016

**Contact Information**

Business Address: Department of Diagnostic Radiology and Nuclear Medicine

University of Maryland Medical Center

22 S. Greene Street

Baltimore, MD 21201

Business Phone Number: (410) 328-6895

Fax: (410) 328-1600

Email: wchen5@umm.edu

Foreign languages: Chinese (native), Japanese (fluent)

**Education**

1981-1987 BM, Shanghai Medical University (now Fudan University), China

1987-1990 MPH, Public Health, Shanghai Medical University

1994-1999 PhD, Molecular and Cell Biology, Graduate School of Medicine, University of Tokyo, Japan

**Post Graduate Education and Training**

* 1. Postdoctoral Research Scientist

Department of Medicine, Columbia University, NY

2005-2006 Internship in Internal Medicine

 Saint Peter’s University Hospital, New Brunswick, NJ

2006-2008 Residency in Nuclear Medicine

Hospital of the University of Pennsylvania, Philadelphia, PA

2008-2009 Fellowship in Nuclear Medicine

 Hospital of the University of Pennsylvania, Philadelphia, PA

**Employment History**

1990-1994 Assistant Professor, Department of Nutrition, School of Public Health, Shanghai Medical University, Shanghai, China

2002-2005 Associate Research Scientist (Research Assistant Professor), Department of Medicine, Columbia University

2009 2009-2014 Assistant Professor, Department of Diagnostic Radiology and Nuclear Medicine,

 University of Maryland School of Medicine

 2014-present Associate Professor, Department of Diagnostic Radiology and Nuclear Medicine,

 University of Maryland School of Medicine

**Certificate**

2009 Diplomat, American Board of Nuclear Medicine

**Medical Licensures**

 2008-2010 State of Pennsylvania, Inactive

2009-present State of Maryland, Active

**Professional Society Memberships**

2005-present General Member, Society of Nuclear Medicine and Molecular Imaging (SNMMI)

2006-present General Member, American College of Nuclear Medicine (ACNM)

2010-present General Member, Radiology Society of North America (RSNA)

1999-2005 American Heart Association (AHA)

**Honors and Awards**

1992 Outstanding Faculty, Shanghai Medical University

1993 Science and Technology Progress Award, Ministry of Public Health, China,

1994-1999 Japanese Government Monbusho Scholarship, Japan

 1999 Representative of all graduating PhD students in the University of Tokyo to receive degree certificate from the President of the University, Japan

2008 Travel Grant Award, 34th ACNM annual meeting

 2008 Honorable Mention of the Siemens Award for Excellence in Practice Based Research, 55th SNMMI annual meeting

 2010 Teaching Award, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine

 2012 Science Council Research Symposium Oral Presentation and the Best in Physics Poster, American Association of Physicists in Medicine Annual Meeting

 2013 First Place Poster - Clinical Diagnosis Track, 59th SNMMI Annual Meeting

 2013 Elite Reviewer, JACC, Journal of the American College of Cardiology

 2014 Third Place Poster - Oncology: Clinical Diagnosis Track, 60th SNMMI Annual Meeting

 2015 SNMMI Future Leaders Academy

 2015- Visiting Professor, Zhongshan Hospital, Fudan University Shanghai Medical School, China

 2016- FACNM, fellow of American College of Nuclear Medicine

**Clinical Activities**

Clinical Expertise

2009-present Full-time Board Certified Nuclear Medicine Physician; Provide services of General Nuclear Medicine imaging, Cardiac Stress Perfusion SPECT, PET/CT, as well as radionuclide therapy including I-131 for hyperthyroidism and thyroid cancer, Radioimunotherapy for non-Hodgkin’s lymphoma, Radionuclides for bone pain palliation and Xofigo (Radium-223) for prostate cancer bone metastases.

Scope of Clinical Practice:

2009-present Primary site: Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland Medical Center.

Also, active faculty staff at the Baltimore VA Medical Center; University of Maryland Medical Center Midtown Campus (formerly Maryland General Hospital); MedStar Union Memorial Hospital; MedStar Good Samaritan Hospital; St. Agnes Hospital

**Administrative Service**

Institutional Service

2009-present Director, Nuclear Medicine Residency Program, UMMC

2009-present Member, GME Committee, UMMC

2009-present Member, Radiation Safety Committee, Human Use Subcommittee

2009-present Member, Radioactive Drug Research Committee

2012-present Member, P&T Subcommittee for Radiology/Nuclear Medicine

Departmental Service

2009-present Member, Educational Committee, Department of Radiology

**Local and National Service**

National Service

2011-presentAbstract Review Panel (Endocrinology and Neuroendocrine tumor sections),SNMMI Annual Meeting Scientific Program Committee

June 2013 Moderator, Thyroid Cancer Session, 59th SNMMI Annual Meeting, 2013

June 2014 Organizer and Moderator, Continuing Education Session, on “Hybrid FDG PET/CT Imaging for Cardiac Device and Prosthetic Valve Infection”, 60th SNMMI annual meeting, St. Louise, MO

June 2015 Organizer, Continuing Education Session, on “Beyond Myocardial Perfusion Imaging with SPECT and PET”, 61th SNMMI annual meeting, Baltimore, MD

2013-2015 Intern, Board of Directors, Cardiovascular Council, SNMMI

2014-present Committee Member, Membership Task Force, SNMMI

2014-2016 Executive Committee, Mid-Eastern Chapter, SNMMI

2015-present Board of Directors, Cardiovascular Council, SNMMI

2016-present Treasure, Mid-Eastern Chapter, SNMMI

2016 Organizer, Continuing Education Session, on “Cardiovascular Inflammation and Infection”, 62nd SNMMI annual meeting, San Diego, CA

2016 Nomination Committee/Blumgart Award, CVC/SNMMI

Journal Editorial Board

2011-present Editorial Board, *Clin Nucl Med*

2011-present Associate Editorial Board, *Am J Nucl Med Mol Imaging*

2015-present Editorial Board, *Applied Radiology*

Journal Reviewer (selected)

2009-present *Clin Nucl Med*

2009-present *JACC: Cardiovascular Imaging*

2011-present *Mol Imaging Biol*

2011-present *Int Cardio Imaging*

2012-present *J Nucl Med*

2012-present *Eur J Nucl Med Mol Imaging*

**Teaching Service**

Medical Student Teaching

2009-present Course Director- Molecular Imaging (NMED 542): 3rd and 4th year medical students: 4 weeks/year

Course Lecturer- Basic Radiology (RADL 540): 3rd and 4th year medical students, 3-4 hours/year

Resident and Fellow Clinical Teaching

2009-present Attending Nuclear Medicine Physician, side-by-side daily clinical education and supervision: 2 Nuclear Medicine residents, 2 Diagnostic Radiology residents, and 2 Cardiology fellows

Resident and Fellow Lecture Teaching

2009-present Lecturer, Nuclear Medicine Residency Program Conference, 1 h/week

 Lecturer, Diagnostic Radiology Residency Program Conference, 1 h /month

Resident Research Mentoring

2010-2013 1 Nuclear Medicine Resident, 2 h/week

Guiding RSNA Resident grant application, and mentoring the project after it was awarded.

Project: 18F-proline PET/CT in the functional diagnosis of early alcoholic liver fibrosis.

Publications: 3 peer reviewed papers (#30, 34, and 35), 4 national meeting abstracts (#17, 20, 21, 23).

The resident was recruited as faculty in the Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine in July 2013, and has been continuing on the same field of research.

2011-2014 1 Nuclear Medicine Resident, 1 h/week

 Guiding research design, data collection, analysis and manuscript writing

Publications: 2 peer reviewed papers (#36 and 38), 1 national meeting abstracts (#25).

2012-2015 1 Nuclear Medicine Resident, 2 h/week

Mentoring RSNA Resident grant application, and supervising research on FDG PET/CT imaging of LVAD infection.

Publications: 2 peer reviewed papers (#32 and 37), 1 national meeting abstracts (#30).

2014-presnt 1 Nuclear Medicine Resident, 1 h/week

Mentoring IRB protocol application, supervising research on “comparison of diagnostic CT vs localizing CT PET in cancer staging”

**Grant Support**

Active Grant:

07/01/2013-06/30/2017 Co-Investigator (6.4% effort), R01CA172638, NIH/NCI

 (PI: Dr. Wei Lu, Department of Radiation Oncology, UMB)

Quantitative PET/CT Analysis to Improve Evaluation of Tumor Response

Role: to assist Dr. Lu in project design, provide extensive PET/CT imaging interpretation, review/perform image registration and tumor segmentation, and evaluate the clinical significance of the results.

 Total Direct Cost of $830,000

08/01/2014-07/31/2017 Co-Investigator (2% effort), Maryland Industrial Partnerships (MIPS), (PI: Dr. Mark Smith, Department of Diagnostic Radiology and Nuclear Medicine, UMB)

 Brain Imaging Device with Motion Compensation

Role: to assist Dr. Smith in project design, provide brain PET/CT interpretation, data analysis and evaluate the clinical significance.

Total Direct Cost of $158,732

07/01/2016-06/30/2020 Co-Investigator (2% effort), R01CA172638, NIH/NCI

 (PI: Dr. Amit Sawant, Department of Radiation Oncology, UMB)

Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR)

Role: to provide extensive V/Q scan and SPECT imaging interpretation, and evaluate the clinical significance of the results.

Completed Grant:

09/01/2012-08/30/2013 Principal Investigator

 UMB/UMD seed fund

18F-Proline PET/CT Imaging for the Detection of Early Liver Fibrosis, Total Direct Costs: $75,000

07/01/2007-06/30/2008 Principal Investigator

 Pilot Research Grant in Molecular Imaging, SNMMI

 Glucose metabolism in macrophage foam cells: Molecular mechanism for FDG-PET imaging of atherosclerosis

 Total Direct Costs: $25,000

Participated Grant:

07/01/2006-06/30/2009 Co-Investigator, 5R01AR048241, NIAMS

 (PI: Dr. Abass Alavi, University of Pennsylvania)

 FDG-PET imaging in painful hip prosthesis

07/01/2006-06/30/2008 Co-Investigator, 5T32CA093258, NCI

 (PI: Dr. Abass Alavi, University of Pennsylvania)

 Training in cancer imaging novel techniques

07/01/2002-06/30/2005 Co-Investigator, 2R01HL022682, NIH/NHLBI

 (PI: Dr. Alan Tall, Columbia University)

 Cholesterol efflux, foam cell formation and diabetes

04/2001/04-06/30/2005 Co-Investigator, 5P50HL056984, NIH/NHLBI

 (PI: Dr. Alan Tall, Columbia University)

 Molecular and cellular mechanisms of cholesterol efflux

Clinical Trial:

10/01/2014 – 9/30/2016 Sub-investigator, Novelos, Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma

01/01/2015 - Present Sub-investigator, Bayer Health Care, Combination radium-223 dichloride/abiraterone/prednisone/prednisolone versus

placebo/abiraterone/prednisone/prednisolone in chemotherapy-naïve subjects with bone predominant metastatic CRPC

04/01/2015 – 6/30/2016 Sub-investigator, Immunomedics, Inc., An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

09/01/2016 – present Sub-investigator,Actinium Pharmaceuticals Inc., A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia.

**Publications**

Peer-reviewed original papers

1. **Chen W**, Kubota S, Nishimura Y, Nozaki S, Yamashita S, Nakagawa T, Kameda-Takemura K, Menju M, Matsuzawa Y, Bjorkhem I, Eggertsen G, Seyama Y. Genetic analysis of a Japanese Cerebrotendinous Xanthomatosis family: identification of a novel mutation in the adrenodoxin binding region of the CYP27 gene. Biochim Biophys Acta. 1996 Nov; 1317(2):119-126.
2. **Chen W**, Kubota S, Kim KS, Cheng J, Kuriyama M, Eggertsen G, Bjorkhem I, Seyama Y. Novel homozygous and compound heterozygous mutations of the sterol 27-hydroxylase gene (CYP27) cause cerebrotendinous xanthomatosis in three Japanese patients from two unrelated families. J Lipid Res. 1997 May; 38(5):870-879.
3. **Chen W**, Kubota S, Teramoto T, Nishimura Y, Yonemoto K, Seyama Y. Silent nucleotide substitution in the sterol 27-hydroxylase gene (CYP27) leads to alternative pre-mRNA splicing by activating a cryptic 5’ splice site at the mutant codon in Cerebrotendinous Xanthomatosis patients. Biochemistry.1998 Mar, 37(3):4420-4428.
4. **Chen W**, Kubota S, Seyama Y. Alternative pre-mRNA splicing of the sterol 27-hydroxylase gene (CYP27) caused by a G to A mutation at the last nucleotide of exon 6 in a patient with Cerebrotendinous Xanthomatosis (CTX).J Lipid Res. 1998 Mar, 39(3):509-517.
5. **Chen W**, Kubota S, Teramoto T, Ishida S, Ohsawa N, Katayama T, Takeda T, Kuroda K, Yahara O, Kusuhara T, Neshige R, Seyama Y. Genetic analysis enables definite and rapid diagnosis of Cerebrotendinous Xanthomatosis. Neurology. 1998 Sep; 51(3):865-867.
6. **Chen W**, Kubota S, Ujike H, Ishihara T, Seyama Y. A novel Arg362Ser mutation in the sterol 27-hydroxylase gene (CYP27): its effects on pre-mRNA splicing and enzyme activity. Biochemistry.1998 Oct, 37(43):15050-15056.
7. Arai T, Rinninger F, Varban L, Fairchild-Huntress V, Liang CP, **Chen W**, Seo T, Deckelbaum R, Huszar D, Tall A. Decreased selective uptake of HDL cholesteryl esters in apoE knock-out mice. Proc Natl Acad Sci U S A. 1999 Oct, 96(21):12050-12055.
8. **Chen W**, Silver D, Smith JD, Tall A. Scavenger receptor BI inhibits ATP binding cassette transporter A1-mediated cholesterol efflux in macrophages.J Biol Chem. 2000 Oct, 275(40):30794-30800.
9. Sugama S, Kimura A, **Chen W**, Kubota S, Seyama Y, Taira N, Eto Y. Frontal lobe dementia with abnormal cholesterol metabolism and heterozygous mutation in sterol 27-hydroxylase gene (CYP27). J Inherit Metab Dis. 2001 Jun, 24(3):379-392.
10. **Chen W**, Sun Y, Welch C, Gorelik A, Leventhal A, Tabas I, Tall A. Preferential ATP-binding cassette transporter A1-mediated cholesterol efflux from late endosomes/lysosomes. J Biol Chem. 2001 Nov, 276(47):43564-43569.
11. Leventhal AR, **Chen W**, Tall A, Tabas I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J Biol Chem. 2001 Nov, 276(48):44976-44983.
12. Wang N, **Chen W**, Linzel-Nitschke P, Martinez LO, Agerholm-Larsen B, Silver DL, Tall A. A PEST sequence in ABCA1 regulates degradation by calpain protease and stabilization of ABCA1 by apoA-I. J Clin Invest. 2003 Jan, 111(1):99-107.
13. Martinez LO, Agerholm-Larsen B, Wang N, **Chen W**, Tall A. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem.2003 Sep, 278(39): 37368-37374.
14. Wang N, Lan D, Gerbod-Giannone M, Linsel-Nitschke P, Jehle AW, **Chen W**, Martinez LO, Tall A. ATP-binding cassette transporter A7 (ABCA7) binds apolipoprotein A-I and mediates cellular phospholipid but not cholesterol efflux. J Biol Chem. 2003 Oct, 278(44):42906-42912.
15. Wang N, Lan D, **Chen W**, Matsuura F, and Tall A. **ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins**. Proc Natl Acad Sci USA 2004 Jan, 101(26):9774-9779.
16. **Chen W**, Nan Wang, Tall A. A PEST deletion mutant of ABCA1 shows impaired internalization and defective cholesterol efflux from late endosomes. J Biol Chem. 2005 Aug, 280(32):29277-29281.
17. Matsuura F, Wang N, **Chen W**, Jiang XC and Alan R. Tall. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest. 2006 May, 116(5):1435-1442.
18. **Chen W**, Botvinick EH, Alavi A, Zhang Y, Yang S, Perini R, Zhuang H. Age-related decrease in cardiopulmonary adrenergic neuronal function in children as assessed by I-123 metaiodobenzylguanidine. J Nucl Cardiol. 2008 Jan, 15(1):73-79.
19. Bural GG, Torigian DA, Chamroonrat W, Houseni M, **Chen W**, Basu S, Kumar R, Alavi A. FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008 Mar, 35(3):562-569.
20. Basu S. **Chen W**, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008 Mar, 112(5):995-1000.
21. **Chen W**, Parson M, Torigian DA, Zhuang H, Alavi A. Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun. 2009 Mar, 30(3):240-244.
22. Bural GG, Torigian DA, Botvinick E, Houseni M, Basu S, **Chen W**, Alavi A. A pilot study of changes in 18F-FDG uptake, calcification and global metabolic activity of the aorta with aging. Hell J Nucl Med. 2009 May, 12(2):123-128.
23. Bural GG, Torigian DA, **Chen W**, Houseni M, Basu S, Alavi A. Increased 18F-FDG uptake within the reticuloendothelial system in patients with active lung cancer on PET imaging may indicate activation of the systemic immune response. Hell J Nucl Med. 2010 Jan, 13(1):23-25.
24. Cheng G, **Chen W**, Chamroonrat W, Torigian DA, Zhuang H, Alavi A. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. 2011 Aug, 38(8):1469-1476.
25. **Chen W**, Zhuang H, Cheng G, Torigian DA, Alavi A. Comparison of FDG-PET, MRI and CT for post radiofrequency ablation evaluation of hepatic tumors. Ann Nucl Med. 2013 Jan, 27(1):58-64.
26. Tan S, Kligerman S, **Chen W**, Lu M, Kim G, Feigenberg S, D’Souza W, Suntharalingam M, Lu W. Spatial-Temporal FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2013 Apr, 85(5): 1375-1382.
27. Tan S, Zhang H,Zhang Y, **Chen W**, D’Souza W, and Lu W. Predicting Pathologic Tumor Response to Chemo-Radiotherapy with Histogram Distances Characterizing Longitudinal Changes in 18F-FDG Uptake Patterns. Med. Physics. 2013, Oct, 40(10):101707.
28. **Chen W,** Codreanu I, Yang J, Li G, Servaes S, and Zhuang H. Tube feeding is increasing the gastric emptying rate determined by gastroesophageal scintigraphy. Clin Nucl Med. 2013, Dec, 38(12):962-965.
29. Zhang H, Tan S, **Chen W**, Kligerman S, Kim G, D’Souza W, Suntharalingam M, and Lu W. Modeling pathologic response of esophageal cancer to chemoradiotherapy using spatial temporal FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys. 2014, Jan, 88(1):195-203.
30. Cao Q, Hersl J, La H, Smith M, Jenkins J, Goloubeva O, Dilsizian V, Tkaczuk K**, Chen W** (corresponding author), Jones L. A pilot study of FDG PET/CT detects a link between brown adipose tissue and breast cancer. BMC Cancer. 2014, Feb, 14(1):126-131.
31. Basu S, Kwee TC, Saboury B, Garino JP, Nelson CL, Zhuang H, Parsons M, **Chen W,** Kumar R, Salavati A, Werner TJ, Alavi A. [FDG PET for Diagnosing Infection in Hip and Knee Prostheses: Prospective Study in 221 Prostheses and Subgroup Comparison With Combined 111In-Labeled Leukocyte/99mTc-Sulfur Colloid Bone Marrow Imaging in 88 Prostheses.](http://www.ncbi.nlm.nih.gov/pubmed/24873788) Clin Nucl Med. 2014, Jul, 39(7):609-615.
32. Kim J, Feller ED, **Chen W**, Dilsizian V. FDG PET/CT Imaging for LVAD Associated Infections. JACC Cardiovasc Imaging. 2014, Aug, 7(8):839-42.
33. Lu W, **Chen W**, Kligerman S, Feigenberg SJ, Zhang H, Suntharalingam M, Kang M and D’Souza WD. Pre-Chemoradiotherapy FDG PET/CT cannot Identify Residual Metabolically-Active Volumes within individual Esophageal Tumors. J Nucl Med Radiat Ther. 2015, May, 6(3):226-232.
34. [Klein T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Klein%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Abdulghani M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Abdulghani%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Smith M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Smith%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Huang R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Huang%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Asoglu R](http://www.ncbi.nlm.nih.gov/pubmed/?term=Asoglu%20R%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Remo BF](http://www.ncbi.nlm.nih.gov/pubmed/?term=Remo%20BF%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Turgeman A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Turgeman%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Mesubi O](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mesubi%20O%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Sidhu S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Sidhu%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Synowski S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Synowski%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Saliaris A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Saliaris%20A%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [See V](http://www.ncbi.nlm.nih.gov/pubmed/?term=See%20V%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Shorofsky S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Shorofsky%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [**Chen W**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20W%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Dilsizian V](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dilsizian%20V%5BAuthor%5D&cauthor=true&cauthor_uid=25713216), [Dickfeld T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dickfeld%20T%5BAuthor%5D&cauthor=true&cauthor_uid=25713216). Three-Dimensional 123I-Meta-Iodobenzylguanidine Cardiac Innervation Maps to Assess Substrate and Successful Ablation Sites for Ventricular Tachycardia: A Feasibility Study for a Novel Paradigm of Innervation Imaging. [Circ Arrhythm Electrophysiol.](http://www.ncbi.nlm.nih.gov/pubmed/25713216) 2015, Jun, 8(3):583-91.
35. Abdulghani M, Duell J, Smith M, **Chen W**, Bentzen SM, Asoglu R, Klein T, Bob-Manuel T, Saliaris A, See V, Shorofsky S, Dilsizian V, Dickfeld T. [Global and Regional Myocardial Innervation Before and After Ablation of Drug-Refractory Ventricular Tachycardia Assessed with 123I-MIBG.](http://www.ncbi.nlm.nih.gov/pubmed/26033905) J Nucl Med. 2015 Jun;56 Suppl 4:52S-8S

Peer reviewed journal invited perspective

1. **Chen W**, Dilsizian V. PET assessment of vascular inflammation and atherosclerotic plaques: SUV or TBR? J Nucl Med. 2015, Apr. 56(4):502-4.

Peer reviewed journal case reports

1. Cao Q, Lu M, Heath J, Hausner P, Alexander HR, Dilsizian V, and **Chen W**. F-18 FDG PET/CT in a Recurrent Diffuse Malignant Peritoneal Mesothelioma. Clin Nucl Med. 2012 May, 37(5):492-494.
2. Cao Q, Lu M, Huebner T, Dilsizian V, and **Chen W**. F-18 FDG PET/CT in a Rare Malignant Extra-Skeletal Osteosarcoma. Clin Nucl Med. 2013, Sep, 38(9):e367-9.
3. Rezaee A, Zhao X, Dilsizian V, and **Chen W**. Pediatric Presentation of Splenic Marginal Zone Lymphoma on FDG PET/CT Scan. Clin Nucl Med. 2014, Feb, 39(2):178-90.
4. Kim J, **Chen W,** Resnik C, Dilsizian V, Chen Q, Kimball AS. FDG uptake in liposclerosing myxofibrous tumor causes upstaging of Hodgkin Lymphoma. Clin Nucl Med. 2015, Apr, 40(4):325-7.
5. Rezaee A, **Chen W**, Dilsizian V, Chen Q, Kimball AS. [Giant Cell Tumor of the Tendon Sheath With Discordant Metabolism as a False Positive on Staging of Mantle Cell Lymphoma.](http://www.ncbi.nlm.nih.gov/pubmed/26053722) Clin Nucl Med. 2015, Oct, 40(10):814-5.

Peer reviewed journal reviews

1. Botvinick EH, Perini R, Rural G, **Chen W**, Chryssikos T, Houseni M, Hernandez-Pampaloni M, Torigian DA, Alavi A. The aging of the heart and blood vessels: a consideration of anatomy and physiology in the era of computed tomography, magnetic resonance imaging, and positron emission tomographic imaging methods with special consideration of atherogenesis.Semin Nucl Med.2007 Mar, 37(2):120-143.
2. **Chen W**, Li G, Alavi A, Zhuang H. Clinical significance of incidental FDG uptake in the thyroid. PET Clinics.2007, 2:321-329.
3. Takalkar A, **Chen W**, Desjardins B, Alavi A. Cardiovascular imaging with PET, CT and MR imaging. PET Clinics. 2008, 3:411-434.
4. Chen K, Blebea J, Laredo J, **Chen W**, Alavi A, Torigian DA. Evaluation of Musculoskeletal disorders with PER, PET/CT and PET/MR imaging. PET Clinics. 2008, 3:451-465.
5. **Chen W**, Bural GG, Torigian DA, Rader D, Alavi A. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2009 Jan, 36(1):144-151.
6. Basu S, Zhuang H, Torigian DA, Rosenbaum J, **Chen W**, Alavi A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med. 2009 Mar, 39:124-145.
7. **Chen W**, Dilsizian V. 18F-Fluorodeoxyglucose PET Imaging of Coronary Atherosclerosis and Plaque Inflammation. Curr Cardiol Rep. 2010 Mar, 12(2):179-184 (invited review).
8. **Chen W**, Cao Q, Dilsizian V. Variation of Heart-to-Mediastinal Ratio in 123I-mBIG Cardiac Sympathetic Imaging: Its Affecting Factors and Potential Corrections. Curr Cardiol Rep. 2011 Apr, 13(2):131-137.
9. Molchanova-Cook O, **Chen W**. Role of FDG-PET in evaluation of myocardial viability. PET Clinics. 2011, 6:383-391.
10. Gurm G, Chirindel A, and **Chen W**. Emerging role of fluorodeoxyglucose-PET in the diagnosis of cardiac sarcoidosis. PET Clinics. 2011, 6:403-408.
11. **Chen W**. Can vascular wall 18F-FDG uptake on PET imaging serve as a biomarker of vulnerable atherosclerotic plaque? PET Clinics. 2011, 6:417-420.
12. Zhang Y, **Chen W**. Radiolabeled glucagon-like peptide-1 analogues: a new pancreatic b-cell imaging agent. Nucl Med Communi, 2012 Mar, 33(3):223-227.
13. **Chen W**, Dilsizian V. Molecular Imaging of Amyloidosis: Will the Heart be the Next Target after the Brain? Curr Cardiol Rep. 2012 Apr, 14(2):226-233.
14. Cao Q, **Chen W**. FDG PET imaging of large vessel vasculitis. PET Clinics. 2012, 7:227-232.
15. Klein T, Dilsizian V, Cao Q, **Chen W**, Dickfeld T. The Potential Role of Iodine-123 *Meta*iodobenzylbuanidine Imaging for Identifying Sustained Ventricular Tachycardia in Patients with Cardiomyopathy.Curr Cardiol Rep. 2013 May, 15(5):359-367.
16. **Chen W**, Dilsizian V. Targeted PET/CT Imaging of vulnerable atherosclerotic plaques: microcalcification of with sodium fluoride and inflammation with fluodeoyglucose. Curr Cardiol Rep. 2013, Jun, 15(6):364-369.
17. **Chen W**, Kim J, Molchanova-Cook O, and Dilsizian V. The Potential of FDG PET/CT for early diagnosis of cardiac device and prosthetic valve infection before morphologic damages ensure. Curr Cardiol Rep. 2014, Mar, 16(3):459-553.
18. [Duell J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Duell%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26783000), [Dilsizian V](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dilsizian%20V%5BAuthor%5D&cauthor=true&cauthor_uid=26783000), [Smith M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Smith%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26783000), [**Chen W**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chen%20W%5BAuthor%5D&cauthor=true&cauthor_uid=26783000), [Dickfeld T](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dickfeld%20T%5BAuthor%5D&cauthor=true&cauthor_uid=26783000). Nuclear Imaging Guidance for Ablation of Ventricular Arrhythmias. [Curr Cardiol Rep.](http://www.ncbi.nlm.nih.gov/pubmed/26783000) 2016 Feb, 18(2):19-26.

Book Chapters

**Wengen Chen**, Henry Gewirtz, Mark Smith, and Vasken Dilsizian. 2012, Animal Models in Cardiology, In: Targeted Molecular Imaging, CRC Press Tayker & Francis Group, Boca Raton, FL, ISBN: 978-1-4398-4195-2

Gang Cheng and **Wengen Chen**.FDG PET/CT is a valuable tool in guiding bone marrow biopsy in the initial evaluation of lymphoma patients. 2012, In: Biopsies: Procedures, Types and Complications. Nova Science Publishers, Hauppauge, NY. ISBN: 978-1-61942-723-5

**Wengen Chen,** Vasken Dilsizian.2016, Autonomic Innervation System in the Heart: Anatomy and Molecular Biology. In: Atlas of Cardiac Innervation. Springer.

**Wengen Chen** and Samar Hajj. 2016, Basic Interpretation. In: Myocardial Perfusion Imaging 2016: Quality, Safety, and Dose Optimization. Society of Nuclear Medicine and Molecular Imaging. ISBN 978-0-932004-94-9

Guest Monograph Editor:

1. **Chen W**, Takalkar A. Cardiac PET Imaging. PET Clinics, 2011, Volume 6, Number 4. W.B. Saunders Company, Philadelphia, PA. ISBN: 978-1-4557-1120-8

Abstracts

* + - 1. **Chen W**, Li G, Dadparvar S, Alavi A, Zhuang H. Factors that affect gastric emptying rate in

children with gastroesophageal reflux study. J Nucl Med. 2007, 48:64

* + - 1. **Chen W**, Yang S, Li G., Alavi A. FDG uptake and calcification in the large arteries of young patients. J Nucl Med. 2007, 48:235.
			2. **Chen W**, Li G, Dadparvar S, Alavi A, Zhuang H. Effect of tube feeding on gastric emptying

rate in children with scintigraphic gastroesophageal reflux study. J Nucl Med. 2007, 48:278.

* + - 1. Li G, **Chen W**, Zhang Y, Zhuang H., Alavi A. The clinical role of FDG-PET in the

assessment of olfactory neuroblastoma. J Nucl Med. 2007, 48:218

* + - 1. Li G, **Chen W**, Dadparvar S., Alavi A., Zhuang H.. What is the optimal duration for

gastroesophageal reflux study in pediatrics? J Nucl Med. 2007, 48:278.

* + - 1. Li G, **Chen W**, Zhang Y, Yang S, Zhuang H., Alavi A. Evaluation of FDG-PET in staging and recurrence of patients with nasal cavity and paranasal sinus carcinoma. J Nucl Med. 2007, 48:35.
			2. **Chen W**, Hochhold JH, Soulen M, Torigian DA, Alavi A, Zhuang H. Role of FDG-PET in the evaluation of tumors treated with radiofrequency ablation. J Nucl Med. 2008, 49:40.
			3. **Chen W**, Li G, Parsons M, Dadparvar S, Torigian DA, Zhuang H, Alavi A. Clinical

significance of incidental focal vs diffuse thyroid uptake on FDG-PET/CT. J Nucl Med. 2008, 49:247.

* + - 1. Li G, **Chen W**, Torigian DA, Zhuang H, Alavi A. Assessment of diagnostic performance of

PET/CT in diagnosis of neck lymph node metastases from head and neck cancer. J Nucl Med. 2008, 49:356.

* + - 1. Li G, Vivino F, **Chen W**, Torigian DA, Zhuang H., Alavi A. Utility of salivary scintigraphy to monitor treatment of Sjogren’s syndrome using rituximab. J Nucl Med. 2008, 49:245.
			2. Chamroonrat W, Houseni M, Servaes S, **Chen W**, Edwards K, Dadparvar S, Zhuang H. Possible shorten time in evaluating gastric emptying rate as part of milk scan studies. J Nucl Med. 2009, 50:67.
			3. **Chen W**, Rader D, Alavi A. Glucose metabolism in plaque macrophages: molecular mechanism for FDG-PET imaging of atherosclerosis. J Nucl Med. 2009, 50:80.
			4. Cheng G, Servaes S, **Chen W**, Li G, Dadparvar S, Alavi A, Zhuang H. FDG PET/CT outperforms diagnostic CT in the initial staging of non-Hodgkin’s lymphoma (NHL) in pediatric patients. J Nucl Med. 2009, 50:167.
			5. Li G, Cheng G, **Chen W**, Zhuang H, Dadparvar S, Alavi A. Accurate anatomical localization in interpretation of PET/CT imaging for patients with head and neck malignancies. J Nucl Med. 2009, 50:200.
			6. Chamroonrat G, Cheng G, Houseni M, Edwards K, **Chen W**, et al. Can the time of milk scan studies be shortened to 45 minutes without compromising the evaluation of the rate of gastric emptying? J Nucl Med. 2010, 51:344.
			7. Molchanova-Cook O, Lu M, **Chen W**, Chirindel A, The role of SPECT and PET in the management of cerebellar disorders. J Nucl Med. 2011, 52:190.
			8. Cao Q, Lu M, **Chen W**. The role of PET/CT in the management of peritoneal mesothelioma. J Nucl Med. 2011, 52:197
			9. Tan S, **Chen W,** Lu M, Kim G, Feigenberg S, D'Souza W, Suntharalingam M, and Lu W. SU-D-BRC-03: Spatial-Temporal PET-CT Features for Predicting Pathological Response of Esophagus Cancer to Chemo-Radiation Therapies, Med. Phys. 2011, 38:3384.
			10. **Chen W**, Dilsizian V. Molecular Imaging of Amyloidosis: Will the heart be the next target after the brain? J Nucl Med. 2012, 53:187.
			11. Cao Q, Lu M, Dilsizian Q, **Chen W**. Thyroid scan in the diagnosis of Marine-Lenhart syndrome. J Nucl Med. 2012, 53:193.
			12. Cao Q, Lu M, Dilsizian Q, **Chen W**. Viability of FDG PET/CT signial and presentation of rare mucinous adenocarcinoma of the pancreas, appendix, ovary and rectum. J Nucl Med. 2012, 53:201.
			13. Cao Q, Lu M, Dilsizian Q, **Chen W**. The role of PET/CT in the management of rare gastric leimyosarcoma. J Nucl Med. 2012, 53:201.
			14. Cao Q, Lu M, Dilsizian Q, **Chen W**. Extraskeletal osteosarcoma: The role of hybrid PET/CT for identifying the primary lesion, presence and extent of metastatic disease and post-therapeutic response. J Nucl Med. 2012, 53:201.
			15. Zhang H, Tan S, **Chen W**, Kligerman S, Kim G, Dsouza W, Suntharalingam M, Lu W. Tumor response models in predicting pathologic response of esophageal cancer to neoadjuvant chemoradiotherapy using spatial-temporal FDG PET features (First place award). J Nucl Med. 2012, 53:273.
			16. Rezaee A, Dilsizian V, **Chen W**. Clinical and FDG PET/CT scan presentation of splenic marginal zone lymphoma. J Nucl Med. 2013, 54:282.
			17. Hussein A, Niekoop M, Dilsizian V, Ego-Osuala K, **Chen W**, Smith M, Beck H, Shams O, See V, Saliaris A, Shorofsky S, Dickfeld T. Contribution of Hibernating Myocardium to the Critical Substrate of Ventricular Tachycardia in Patients with Ischemic Heart Disease: A Three-dimensional Positron Emission Tomography Guided Study in Patients Undergoing Radiofrequency Ablation. Heart Rhythm 2014;11(5S):S527(86)
			18. Hussein A, Dilsizian V, **Chen W**, Smith M, Beck H, Shams O, See V, Saliaris A, Shorofsky S, Dickfeld T. Assessment of the Metabolic substrate of Non-ischemic Ventricular Tachycardia by Positron Emission Tomography: Electrophysiological Correlates in Patients Undergoing Radiofrequency Ablation. Heart Rhythm 2014;11(5S):S527(87)
			19. Remo B, Kim J, Beck H, Klein T, Saliaris A, See V, Shorofsky S, Smith M, **Chen W**, Dilsizian V, Dickfeld T. Fluorine-18 Positron Emission Tomography (18F-FDG PET) to Assess Cardiovascular Implantable Electronic Devices (CIED) Infections: Real Life Experience From a Tertiary Extraction Center. Heart Rhythm 2014;11(5S):S115(46).
			20. Tan S, **Chen W**, Li H, D’Souza W, Lu W. Multi-Modality adaptive region-growing for tumor segmentation in 18F-FDG PET/CT. J Nucl Med. 2014, 55:259.
			21. Kim J, **Chen W**, Rezaee A, Zhang J, Molchanova-Cook O, Smith M, Sorensen E, Feller E, Dilsizian V. The utility of FDG PET/CT for localizing left ventricular assist device infection: implications on patient management and outcome. J Nucl Med. 2014, 55:379.
			22. Lu W, Tan S, Zhang H, **Chen W**, Kligerman S, Suntharalingam M, D’Souza W, Quantitative 18F-FDG PET/CT image features for the evaluation of tumor response. J Nucl Med. 2014, 55:1611.
			23. Kim J, Feller E, Chen W, Dilsizian V, The presence and site of left ventricular assist device infection by FDG PET/CT bears important prognostic implications. J Nucl Med. 2015, 56:310

**Major Invited Speeches**

Local

1. **Chen W,** Nuclear Medicine in thyroid nodule and hyperthyroidism management. Department of Endocrinology, UMMC, Baltimore, September 10, 2009
2. **Chen W,** Nuclear Medicine in thyroid cancer management. Department of Endocrinology, UMMC, Baltimore, December 11, 2009
3. **Chen W,** Role of FDG PET/CT imaging for GI cancers, The 2nd Annual GI Cancer Symposium, Greenebaum cancer center, UMMC, Baltimore, MD, April 30, 2010
4. **Chen W,** Radioiodine ablation for thyroid cancer. Department of Endocrinology, UMMC, Baltimore, January 06, 2011
5. **Chen W,** Potential role of FDG PET/CT in atherosclerosis imaging, Nuclear Medicine, John Hopkins University, Baltimore, MD, January 13, 2011
6. **Chen W,** Grand Round: Functional SPECT and PET imaging for Parkinsonism syndrome and Alzheimer’s disease. Department of Neurology, UMMC, Baltimore, May 30, 2012
7. **Chen W,** Radioimmunotherapy for Non-Hodgkin’s lymphoma, Department of Radiation Oncology, UMMC,Baltimore, MD, June 20, 2012
8. **Chen W,** FDG PET/CT in oncology, a clinical user’s guidance, VA Medical Center, Baltimore, MD, September 17, 2012
9. **Chen W,** PET for metabolic imaging of cancer, Clinical Correlation Conference re Metabolic Derangements in Cancer Cells for Medical Students, University of Maryland School of Medicine, Baltimore, January 3, 2013
10. **Chen W,** Grand Round: FDG PET/CT for thyroid cancer. Department of Endocrinology, UMMC, Baltimore, February 11, 2013
11. **Chen W,** Pediatric GI nuclear medicine studies. Pediatric GI Division, UMMC, Baltimore, March 21, 2013
12. **Chen W,** Molecular Imaging. Department of Radiation Oncology, UMMC,Baltimore, MD, November 20, 2012
13. **Chen W,** PET/CT overview. MedStar Health Imaging Service Seminar. Union Memorial Hospital, Baltimore, MD, February 22, 2014.
14. **Chen W,** Grand Round, New FDA approved radiotracers for imaging Parkinson’s and Alzheimer’s diseases. Providence Hospital, Washington, DC, June 26, 2014.
15. **Chen W,** Nuclear Medicine studies in thyroid disorders. Department of Endocrinology, MTC/UMMC, Baltimore, MD, October 16, 2014.
16. **Chen W,** Residency training in the US. Association of Chinese American Physicians, Mid-Atlantic Chapter, Rockville, MD, June 10, 2015.
17. **Chen W,** Molecular Imaging, focusing on PET/CT. Radiation Biology Residency Program, Department of Radiation Oncology, UMMC,Baltimore, MD, March 9, 2016
18. **Chen W,** Use ofPET/CT in community hospitals. Association of Chinese American Physicians, Mid-Atlantic Chapter, Rockville, MD, June 5, 2016.
19. **Chen W,** Nuclear Medicine in thyroid disorders. Department of Endocrinology, Midtown campus, University of Maryland Medical Center, MD, September 23, 2016.

National

1. **Chen W**, Scope of FDG PET/CT in arterial plaque imaging, SNM continuing education, 58th SNMMI annual meeting, San Antonio, TX, June 05, 2011
2. **Chen W,** FDG PET/CT for cardiac device and prosthetic valve infection imaging,SNMMI continuing education, 60th SNMMI annual meeting, St. Louise, MO, June 7, 2014.
3. **Chen W,** Identifying Cardiac Device Infection with FDG PET/CT,SNMMI continuing education, 61th SNMMI annual meeting, Baltimore, MD, June 10, 2015
4. **Chen W,** Role of FDG PET/CT in cardiac device infections, SNMMI continuing education, 62nd SNMMI annual meeting, San Diego, CA, June 14, 2016

International

1. **Chen W**, FDG PET/CT imaging of vulnerable atherosclerotic plaque. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University Shanghai Medical School, Shanghai, China, September 24, 2012
2. **Chen W**, Role of FDG PET/CT in the diagnosis of cardiac device infection. Department of Nuclear Medicine, Zhongshan Hospital, Fudan University Shanghai Medical School, Shanghai, China, January 27, 2014
3. **Chen W,** FDG PET/CT for left ventricular assist device infection: Clinical significance and prognosis.15th Annual Symposium on Nuclear Cardiology, Chinese Society of Nuclear Medicine, Shunde, China, December 15, 2014
4. **Chen W,** Nuclear Medicine Residency training in the United States.Department of Nuclear Medicine, Zhongshan Hospital, Fudan University Shanghai Medical School, Shanghai, China, December 20, 2014
5. **Chen W,** Keynote Speech: FDG PET/CT in Lymphoma Management. Shanghai International Symposium for Medical Image Fusion Technology and Clinical Applications. Shanghai, August 28, 2015.
6. **Chen W,** application of PET/CT in cancer and non-cancer diseases. Online lecture for Chinese Medical Residents. March 20, 2016.
7. **Chen W,** Brown adipose tissue on FDG PET/CT and breast cancer. The 2nd Global Conference of Chinese Professionals in Nuclear Medicine and Molecular Imaging. Chinese Society of Nuclear Medicine, Shenzhen, October 29, 2016
8. **Chen W,** How to correctly understand a nuclear medicine procedure guidance?Department of Nuclear Medicine, Zhongshan Hospital, Fudan University Shanghai Medical School, Shanghai, China, November 4, 2016.